Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1961 1
1964 1
1971 1
1977 1
1978 1
1979 3
1980 2
1981 2
1982 4
1983 1
1984 5
1985 2
1986 4
1987 5
1988 1
1989 3
1990 2
1991 1
1992 2
1993 3
1994 7
1995 2
1996 1
1997 4
1998 5
1999 12
2000 11
2001 18
2002 16
2003 27
2004 25
2005 23
2006 30
2007 32
2008 42
2009 42
2010 68
2011 80
2012 89
2013 67
2014 97
2015 91
2016 90
2017 78
2018 95
2019 121
2020 121
2021 135
2022 120
2023 114
2024 108
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,632 results

Results by year

Filters applied: . Clear all
Page 1
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. Desai J, et al. Among authors: lu ch. J Immunother Cancer. 2020 Jun;8(1):e000453. doi: 10.1136/jitc-2019-000453. J Immunother Cancer. 2020. PMID: 32540858 Free PMC article. Clinical Trial.
Decitabine-induced effusions.
Chen CC, Gau JP, You JY, Lu CH, Chan CH, Lin JT, Lee KD. Chen CC, et al. Among authors: lu ch. Leuk Res. 2009 Sep;33(9):e150-1. doi: 10.1016/j.leukres.2008.11.028. Epub 2009 Jan 20. Leuk Res. 2009. PMID: 19157543 No abstract available.
Targeting HSF1 for cancer treatment: mechanisms and inhibitor development.
Chin Y, Gumilar KE, Li XG, Tjokroprawiro BA, Lu CH, Lu J, Zhou M, Sobol RW, Tan M. Chin Y, et al. Among authors: lu ch. Theranostics. 2023 Apr 17;13(7):2281-2300. doi: 10.7150/thno.82431. eCollection 2023. Theranostics. 2023. PMID: 37153737 Free PMC article. Review.
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Salani R, McCormack M, Kim YM, Ghamande S, Hall SL, Lorusso D, Barraclough L, Gilbert L, Guzman Ramirez A, Lu CH, Sabatier R, Colombo N, Hu Y, Krishnan V, Molinero L, Feng Y, Kim N, Castro M, Lin YG, Monk BJ. Salani R, et al. Among authors: lu ch. Int J Gynecol Cancer. 2024 Aug 5;34(8):1140-1148. doi: 10.1136/ijgc-2024-005588. Int J Gynecol Cancer. 2024. PMID: 38858106 Clinical Trial.
Indocyanine green: An old drug with novel applications.
Lu CH, Hsiao JK. Lu CH, et al. Tzu Chi Med J. 2021 Apr 1;33(4):317-322. doi: 10.4103/tcmj.tcmj_216_20. eCollection 2021 Oct-Dec. Tzu Chi Med J. 2021. PMID: 34760625 Free PMC article. Review.
1,632 results